The estimated Net Worth of David W. Ghesquiere is at least $1.67 Milión dollars as of 16 March 2020. Mr. Ghesquiere owns over 3,177 units of Nanostring Technologies Inc stock worth over $7,537 and over the last 11 years he sold NSTG stock worth over $204,517. In addition, he makes $1,455,550 as Senior Vice President - Corporate and Business Development at Nanostring Technologies Inc.
Sign up
Mr. Ghesquiere NSTG stock SEC Form 4 insiders trading
David has made over 11 trades of the Nanostring Technologies Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 3,177 units of NSTG stock worth $335 on 16 March 2020.
The largest trade he's ever made was exercising 22,000 units of Nanostring Technologies Inc stock on 27 February 2020 worth over $275,000. On average, David trades about 2,811 units every 40 days since 2013. As of 16 March 2020 he still owns at least 71,577 units of Nanostring Technologies Inc stock.
You can see the complete history of Mr. Ghesquiere stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Ghesquiere biography
David W. Ghesquiere serves as Senior Vice President - Corporate and Business Development of the Company. Prior to joining our company, Mr. Ghesquiere was the founder and managing director of Adrenaline Venture & Advisory LLC, an international advisory firm, from August 2012 to November 2013. Prior to founding Adrenaline Venture & Advisory, Mr. Ghesquiere served as Senior Vice President, Corporate & Business Development at Dendreon Corporation, a biotechnology company, from 2011 to 2012. From 2005 to 2010, Mr. Ghesquiere held a variety of executive positions at OSI Pharmaceuticals, acquired by Astellas Pharma in 2010, including Senior Vice-President of Corporate & Business Development and Managing Director of OSI Investment Holdings GmbH and OSI Investment Management GmbH, OSI’s wholly owned, Switzerland-based subsidiaries, where he played a key role in establishing OSI’s venture capital arm. Earlier in his career, Mr. Ghesquiere served as Director of Global Business Development for Aventis Pharmaceuticals, which merged with Sanofi in 2004, and worked in product marketing at Johnson & Johnson. Mr. Ghesquiere received an M.B.A. from The University of Western Ontario’s Ivey School of Business and a B.A. in economics from The University of Western Ontario.
What is the salary of David Ghesquiere?
As the Senior Vice President - Corporate and Business Development of Nanostring Technologies Inc, the total compensation of David Ghesquiere at Nanostring Technologies Inc is $1,455,550. There are 4 executives at Nanostring Technologies Inc getting paid more, with R. Bradley Gray having the highest compensation of $7,288,840.
How old is David Ghesquiere?
David Ghesquiere is 53, he's been the Senior Vice President - Corporate and Business Development of Nanostring Technologies Inc since 2013. There are 13 older and 4 younger executives at Nanostring Technologies Inc. The oldest executive at Nanostring Technologies Inc is William Young, 75, who is the Independent Chairman of the Board.
What's David Ghesquiere's mailing address?
David's mailing address filed with the SEC is 530 Fairview Ave N, Seattle, WA 98109, USA.
Insiders trading at Nanostring Technologies Inc
Over the last 11 years, insiders at Nanostring Technologies Inc have traded over $114,083,977 worth of Nanostring Technologies Inc stock and bought 981,722 units worth $9,126,410 . The most active insiders traders include Charles P Jr Waite, Lifesciences Ii, L.P.Clarus... a Nicholas Galakatos. On average, Nanostring Technologies Inc executives and independent directors trade stock every 16 days with the average trade being worth of $4,371. The most recent stock trade was executed by Joseph M Beechem on 6 May 2024, trading 147,853 units of NSTG stock currently worth $15,569.
What does Nanostring Technologies Inc do?
nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali
What does Nanostring Technologies Inc's logo look like?
Complete history of Mr. Ghesquiere stock trades at Nanostring Technologies Inc
Nanostring Technologies Inc executives and stock owners
Nanostring Technologies Inc executives and other stock owners filed with the SEC include:
-
R. Bradley Gray,
President, Chief Executive Officer, Director -
K. Thomas Bailey,
Chief Financial Officer -
Joseph Beechem,
Senior Vice President - Research and Development -
John Brown,
Senior Vice President - Sales and Marketing -
David Ghesquiere,
Senior Vice President - Corporate and Business Development -
R. Bradley Gray,
CEO, Pres & Director -
K. Thomas Bailey M.B.A.,
Chief Financial Officer -
Dr. Joseph M. Beechem,
Chief Scientific Officer and Sr. VP of R&D -
J. Chad Brown,
Sr. VP of Sales & Marketing -
David W. Ghesquiere,
Sr. VP of Corp. & Bus. Devel. -
William Young,
Independent Chairman of the Board -
Gregory Norden,
Independent Director -
Don Kania,
Independent Director -
Charles Waite,
Independent Director -
Elisha Finney,
Independent Director -
Kirk Malloy,
Independent Director -
Robert Hershberg,
Independent Director -
Elizabeth Schneider Ph.D.,
Sr. Global Marketing Mang. -
Dr. Philippa Webster Ph.D.,
Sr. Principal Scientist -
Dr. Mary Tedd Allen,
Sr. VP of Strategic Initiatives -
Kathryn Surace-Smith,
Sr. VP of HR & Legal Affairs and Corp. Sec. -
Douglas S. Farrell,
VP of Investor Relations & Corp. Communications -
Mark A. Winham,
Sr. VP of Operations -
Teresa M. Foy,
Director -
Nicholas Galakatos,
Director -
Lifesciences Ii, L.P.Clarus...,
-
Wayne Burns,
SVP, Operations & Admin -
James A Johnson,
Chief Financial Officer -
J. Chad Brown,
SVP, Sales & Marketing -
Mary Tedd Allen,
SVP, Operations -
Lifesciences Ii, L.P.Clarus...,
-
Barney Saunders,
SVP & GM, Life Sciences -
Venture Partners Vi Lpovp V...,
-
Fisher Jurvetson Fund Vii, ...,
-
Finny Kuruvilla,
Director -
Tina Susan Nova,
Director -
Bruce J. Seeley,
SVP & GM, Diagnostics -
J Wayne Cowens,
Chief Medical Officer -
Jennifer Scott Fonstad,
Director -
Bradford Crutchfield,
Director -
Janet George,
Director -
Dana E. Rollison,
Director -
John D. Gerace,
Chief Commercial Officer -
Jonathan Todd Garland,
Chief Commercial Officer